A collaborative study from researchers at the Moffitt Cancer Center and Dana-Farber Cancer Institute has uncovered a mechanism of drug resistance to Venetoclax®, also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. BCL-2 is a protein that promotes cell survival and is highly deregulated in […]
The post Lymphoma Resistance Mechanism to Chemo Drug Identified appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Lymphoma Resistance Mechanism to Chemo Drug Identified